{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:18:04Z","timestamp":1788427084293,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005247","name":"University of British Columbia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005247","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.atherosclerosis.2026.120646","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T07:34:47Z","timestamp":1769672087000},"page":"120646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Assessment of LDL receptor-dependent lipid lowering therapies in patients with homozygous familial hypercholesterolemia according to functional genotype"],"prefix":"10.1016","volume":"414","author":[{"given":"G.B.John","family":"Mancini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Ryomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia","family":"Iatan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Genest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick J.","family":"Raal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul D.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula","family":"Marte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke A.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam R.","family":"Brunham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gaudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Larouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Brisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hegele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2023","key":"10.1016\/j.atherosclerosis.2026.120646_bib1","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","article-title":"Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study","volume":"399","author":"Tromp","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib3","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029175","article-title":"Contemporary homozygous familial hypercholesterolemia in the United States: insights from the CASCADE FH registry","volume":"12","author":"Cuchel","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ph16010064","article-title":"Current treatment options in homozygous familial hypercholesterolemia","volume":"16","author":"Kayikcioglu","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib6","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1093\/eurjpc\/zwae144","article-title":"Current treatments for the management of homozygous familial hypercholesterolaemia: a systematic review and commentary","volume":"31","author":"Gu","year":"2024","journal-title":"European journal of preventive cardiology"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11883-024-01269-5","article-title":"Homozygous familial hypercholesterolemia treatment: new developments","volume":"27","author":"Blom","year":"2025","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib8","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehae325","article-title":"Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy","volume":"45","author":"Gaudet","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.atherosclerosis.2016.03.009","article-title":"Phenotype diversity among patients with homozygous familial hypercholesterolemia: a cohort study","volume":"248","author":"Raal","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib10","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jacl.2016.04.009","article-title":"Familial hypercholesterolemia\/autosomal dominant hypercholesterolemia: molecular defects, the LDL-C continuum, and gradients of phenotypic severity","volume":"10","author":"Foody","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib11","article-title":"GENetic characteristics and REsponse to lipid-lowering therapy in familial hypercholesterolemia: GENRE-FH study","volume":"10","author":"Kim","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib12","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacc.2019.12.020","article-title":"Long-Term evolocumab in patients with familial hypercholesterolemia","volume":"75","author":"Santos","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib13","article-title":"Homozygous familial hypercholesterolemia in Canada: an observational Study, JACC","volume":"2","author":"Brown","year":"2023","journal-title":"Advances"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib14","doi-asserted-by":"crossref","DOI":"10.51731\/cjht.2023.572","article-title":"Design, rationale, and preliminary results of the Canadian homozygous familial hypercholesterolemia registry: 2008 to 2022 update","volume":"3","author":"Brown","year":"2023","journal-title":"Canadian Journal of Health Technologies"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.atherosclerosis.2014.11.009","article-title":"Familial hypercholesterolemia in Brazil: cascade screening program, clinical and genetic aspects","volume":"238","author":"Jannes","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib16","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.atherosclerosis.2018.06.822","article-title":"Heterozygous familial hypercholesterolaemia in specialist centres in South Africa, Australia and Brazil: importance of early detection and lifestyle advice","volume":"277","author":"Pang","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib17","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1161\/ATVBAHA.120.315040","article-title":"Cascade screening for familial hypercholesterolemia in South Africa: the Wits FIND-FH Program","volume":"40","author":"Raal","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib18","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/eurheartj\/ehx317","article-title":"Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol","volume":"39","author":"Thompson","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib19","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib20","first-page":"1","article-title":"Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration, atherosclerosis","volume":"22","author":"Vallejo-Vaz","year":"2016","journal-title":"Supplement"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib21","article-title":"Imputation of untreated LDL-C in treated subjects with homozygous familial hypercholesterolaemia: an international collaboration","volume":"412","author":"Mancini","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jacbts.2024.10.006","article-title":"Large-Scale functional characterization of low-density Lipoprotein receptor gene variants improves risk assessment in cardiovascular disease","volume":"10","author":"Islam","year":"2025","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib23","article-title":"The functional landscape of coding variation in the familial hypercholesterolemia gene LDLR","author":"Tabet","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib24","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s12325-023-02764-y","article-title":"The effect of PCSK9 inhibitors on LDL-C target achievement in patients with homozygous familial hypercholesterolemia: a retrospective cohort analysis","volume":"41","author":"Alshahrani","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib25","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1161\/ATVBAHA.122.317793","article-title":"Efficacy and safety of alirocumab in children and adolescents with homozygous familial hypercholesterolemia: phase 3, multinational open-label Study","volume":"42","author":"Bruckert","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","article-title":"Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH trial","volume":"76","author":"Blom","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib27","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.jacl.2017.08.016","article-title":"Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia","volume":"11","author":"Defesche","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10557-023-07505-5","article-title":"Does genotype affect the efficacy of PCSK9 inhibitors in the treatment of familial hypercholesterolemia?","volume":"39","author":"Tandirerung","year":"2025","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib29","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurjpc\/zwae036","article-title":"Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry","volume":"31","author":"D'Erasmo","year":"2024","journal-title":"European journal of preventive cardiology"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib30","article-title":"Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: the SAFEHEART follow-up study","volume":"393","author":"Alonso","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib31","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jacl.2024.11.003","article-title":"Ezetimibe in the management of homozygous familial hypercholesterolaemia","volume":"19","author":"Mansfield","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib32","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1194\/jlr.M300309-JLR200","article-title":"Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia","volume":"45","author":"Bilz","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib33","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.atherosclerosis.2020.11.013","article-title":"Statin therapy reduces plasma angiopoietin-like 3 (ANGPTL3) concentrations in hypercholesterolemic patients via reduced liver X receptor (LXR) activation","volume":"315","author":"Reeskamp","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9010219","article-title":"A real-world experience of clinical, biochemical and genetic assessment of patients with homozygous familial hypercholesterolemia","volume":"9","author":"Di Taranto","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.atherosclerosis.2026.120646_bib35","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.atherosclerosis.2007.06.028","article-title":"A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia","volume":"197","author":"Marais","year":"2008","journal-title":"Atherosclerosis"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026000122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026000122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T09:15:00Z","timestamp":1773998100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915026000122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":35,"alternative-id":["S0021915026000122"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120646","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of LDL receptor-dependent lipid lowering therapies in patients with homozygous familial hypercholesterolemia according to functional genotype","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120646","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120646"}}